SCHEMBL189126

SCHEMBL189126

O=c1oc(-c2ccc(OCc3ccccc3)cc2)ns1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 5/20 0.63
GSTP1 P09211 2/20 0.52
MAOB P27338 3/20 0.50
MAOA P21397 1/20 0.48
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MGAM O43451 1/20 0.47
GAA P10253 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47
PSMB11 A5LHX3 1/20 0.47
PSMD11 O00231 1/20 0.47
PSMD12 O00232 1/20 0.47
PSMD14 O00487 1/20 0.47
PSMA7 O14818 1/20 0.47
PSMD3 O43242 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17502570 0.82 PSMB8 (0.44) PSMB8GSTP1MEN1NPC1RAB9A
SCHEMBL1781069 0.78 PSMB8 (1.00) PSMB8NPC1RAB9ASMN1; SMN2PSMB11
SCHEMBL7301708 0.75 NOTUM (0.62) GSTP1MAOBMEN1KMT2A
SCHEMBL1425626 0.74 PSMB8 (0.62) PSMB8NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL197017 0.73 LMNA (0.72) GSTP1MAOBMAOAMEN1NPC1
SCHEMBL9627131 0.72 PSMB8 (0.68) PSMB8PSMB11PSMD11PSMD12PSMD14
SCHEMBL27501768 0.72 LTA4H (0.69) GSTP1MAOBMAOAMEN1NPC1
SCHEMBL29032391 0.71 KDM4E (0.64) MAOBMAOAMEN1NPC1POLB
SCHEMBL12171570 0.71 NR4A2 (0.70) MAOBMEN1NPC1POLBRAB9A
SCHEMBL14755690 0.71 PSMB8 (0.62) PSMB8NPC1RAB9ASMN1; SMN2PSMB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
US-8492414-B2 Antibacterial agents BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-07-23 US disclosed
US-8492414-B2 Antibacterial agents BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-07-23 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
EP-2200991-B1 ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-03-23 EP disclosed
US-20100273837-A1 ANTIBACTERIAL AGENTS BIOTA EUROPE LTD. (GB) 2010-10-28 US disclosed
US-20100273837-A1 ANTIBACTERIAL AGENTS BIOTA EUROPE LTD. (GB) 2010-10-28 US disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed
EP-2200991-A1 ANTIBACTERIAL AGENTS Biota Europe Ltd (GB) 2010-06-30 EP disclosed
WO-2009037485-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 PSMB8 1826/4885GSTP1 808/4885MAOB 1/4885
US-20100273837-A1 ANTIBACTERIAL AGENTS SQOR, SCO2, CYCS PSMB8 2940/4885GSTP1 227/4885MAOB 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.